



(11)

**EP 3 514 235 B8**

(12)

**KORRIGIERTE EUROPÄISCHE PATENTSCHRIFT**

(15) Korrekturinformation:  
**Korrigierte Fassung Nr. 1 (W1 B1)**  
**Korrekturen, siehe**  
**Bibliographie INID code(s) 73**

(51) Internationale Patentklassifikation (IPC):  
**C12N 15/113** <sup>(2010.01)</sup> **A61K 31/7088** <sup>(2006.01)</sup>  
**A61P 1/00** <sup>(2006.01)</sup>

(48) Corrigendum ausgegeben am:  
**14.02.2024 Patentblatt 2024/07**

(52) Gemeinsame Patentklassifikation (CPC):  
**C12N 15/113; C12N 15/1136; C12N 2310/127**

(45) Veröffentlichungstag und Bekanntmachung des  
Hinweises auf die Patenterteilung:  
**03.01.2024 Patentblatt 2024/01**

(21) Anmeldenummer: **18152422.4**

(22) Anmeldetag: **18.01.2018**

(54) **ZUSAMMENSETZUNG ZUR BEHANDLUNG EINES AN COLITIS ULCEROSA LEIDENDEN  
PATIENTEN SOWIE VERWENDUNG DER ZUSAMMENSETZUNG ALS ARZNEIMITTEL**

COMPOSITION FOR THE TREATMENT OF A PATIENT SUFFERING FROM ULCERATIVE COLITIS  
AND UTILISATION OF SAID COMPOSITION AS MEDICAMENT

COMPOSITION DESTINÉE AU TRAITEMENT DE PATIENTS SOUFFRANT D'UNE COLITE  
ULCEREUSE AINSI QUE L'UTILISATION DE LADITE COMPOSITION EN TANT QUE MÉDICAMENT

(84) Benannte Vertragsstaaten:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

(43) Veröffentlichungstag der Anmeldung:  
**24.07.2019 Patentblatt 2019/30**

(73) Patentinhaber: **Sterna Biologicals GmbH  
35039 Marburg (DE)**

(72) Erfinder: **Renz, Jonas  
81675 München (DE)**

(74) Vertreter: **Pharma Patents International AG  
Leonhardsgraben 52  
Postfach  
4001 Basel (CH)**

(56) Entgegenhaltungen:  
**WO-A1-2017/205506 WO-A2-2005/033314  
WO-A2-2014/040891 US-A1- 2003 040 497**

- **POPP VANESSA ET AL: "Rectal Delivery of a DNase That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, Bd. 152, Nr. 1, 14. September 2016 (2016-09-14), Seiten 176-192, XP029851140, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2016.09.005**
- **Anonymous: "DRKS-ID: DRKS00007193 SB012 for the Treatment of Active Ulcerative Colitis (SECURE): a Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy, Pharmacokinetics, Tolerability, and Safety of SB012 Enema Administered Once Daily", , 9. Juni 2015 (2015-06-09), XP055476967, Gefunden im Internet: URL:[http://www.drks.de/drks\\_web/navigate.do?navigationId=trial.HTML&TRIAL\\_ID=DRKS00007193](http://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007193) [gefunden am 2018-05-18]**

Anmerkung: Innerhalb von neun Monaten nach Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents im Europäischen Patentblatt kann jedermann nach Maßgabe der Ausführungsordnung beim Europäischen Patentamt gegen dieses Patent Einspruch einlegen. Der Einspruch gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet worden ist. (Art. 99(1) Europäisches Patentübereinkommen).

**EP 3 514 235 B8**

- WEIGMANN BENNO ET AL: "Suppression of Experimental Ulcerative Colitis by Topical Delivery of Specific Dnzyme Blocking Thetranscription Factor GATA3", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, 22. April 2017 (2017-04-22), XP085104521, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(17)32631-8
- KATRINA RAY: "A role for GATA3 in ulcerative colitis", NATURE REVIEWS / GASTROENTEROLOGY & HEPATOLOGY, Bd. 13, Nr. 11, 5. Oktober 2016 (2016-10-05), Seiten 624-624, XP55476486, US ISSN: 1759-5045, DOI: 10.1038/nrgastro.2016.163
- ALESYA A. FOKINA ET AL: "Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials", EXPERT OPINION ON DRUG DELIVERY, Bd. 14, Nr. 9, 7. Dezember 2016 (2016-12-07), Seiten 1077-1089, XP55476495, GB ISSN: 1742-5247, DOI: 10.1080/17425247.2017.1266326
- URBANSKA ALEKSANDRA M ET AL: "What's Next for Gastrointestinal Disorders: No Needles?", JOURNAL OF CONTROLLED RELEASE, Bd. 221, 2. Dezember 2015 (2015-12-02), Seiten 48-61, XP029383249, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.11.031
- Zhijie Xu ET AL: "Small-molecule Nucleic-acid-based Gene-silencing Strategies" In: "Nucleic Acids - From Basic Aspects to Laboratory Tools", 16. März 2016 (2016-03-16), InTech, XP55476951, ISBN: 978-953-51-2264-7 DOI: 10.5772/62137, \* Tabelle 2 \*
- HOLGER GARN ET AL: "GATA-3-specific DNzyme - A novel approach for stratified asthma therapy", EUROPEAN JOURNAL OF IMMUNOLOGY, Bd. 47, Nr. 1, 2. Dezember 2016 (2016-12-02), Seiten 22-30, XP055476945, ISSN: 0014-2980, DOI: 10.1002/eji.201646450
- COMINELLI FABIO ET AL: "Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?", CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY JUL 2017, vol. 4, no. 1, July 2017 (2017-07), pages 19-32, ISSN: 2352-345X
- KOELINK PJ AND TE VELDE AA: "Mistakes in mouse models of IBD and how to avoid them.", UEG EDUCATION, vol. 16, 2016, pages 11-14,
- NGUYEN THI LOAN ANH ET AL: "How informative is the mouse for human gut microbiota research?", DISEASE MODELS & MECHANISMS JAN 2015, vol. 8, no. 1, January 2015 (2015-01), pages 1-16, ISSN: 1754-8411
- ALDARS-GARCÍA LAILA ET AL: "The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review.", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 17 MAR 2021, vol. 22, no. 6, 17 March 2021 (2021-03-17) , ISSN: 1422-0067
- CROUWEL FEMKE ET AL: "Gut microbiota-driven drug metabolism in inflammatory bowel disease.", JOURNAL OF CROHN'S & COLITIS 11 JUL 2020, 11 July 2020 (2020-07-11), ISSN: 1876-4479
- VALATAS VASSILIS ET AL: "The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY DEC 2013, vol. 305, no. 11, December 2013 (2013-12), pages G763-G785, ISSN: 1522-1547
- VICTOR JULIAN ET AL: "Inability of DNzymes to cleave RNA in vivo is due to limited Mg[Formula: see text] concentration in cells.", EUROPEAN BIOPHYSICS JOURNAL : EBJ MAY 2018, vol. 47, no. 4, May 2018 (2018-05), pages 333-343, ISSN: 1432-1017
- TRAPANI VALENTINA ET AL: "Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel.", INFLAMMATORY BOWEL DISEASES 15 09 2018, vol. 24, no. 10, 15 September 2018 (2018-09-15), pages 2198-2210, ISSN: 1536-4844
- SWANSON KENNETH D ET AL: "Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.", CURRENT OPINION IN GASTROENTEROLOGY 11 2018, vol. 34, no. 6, November 2018 (2018-11), pages 384-391, ISSN: 1531-7056